The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Objective Gastrointestinal bleeding (GIB) risk in relation to concomitant treatment with non-vitamin K oral anticoagulants (NOAC) and oral glucocorticoids is insufficiently explored. We aimed to ...

The RCTs included in this review have assessed a broad range of treatments that resulted in ... others simply monitored nasogastric output for bleeding). Furthermore, because the majority of ...

Given that over 60% of lesions causing an upper GI bleed are typically low risk for rebleeding, antiplatelet therapy can be safely reintroduced within 24 h in most patients.

Baseline characteristics were balanced with inverse probability of treatment weighting. 30-day all-cause mortality ... for patients newly admitted from the Accident and Emergency Department (AED) with ...

People may need to continue taking oral contraceptives after the initial bleeding is under control. Treatment plans for atypical uterine bleeding will depend on individual factors, including the ...

Acute gastrointestinal bleeding and perforation are important clinical concerns, traditionally associated with high mortality rates. Advances in clinical practice over the past two decades are ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

While not everyone with Crohn’s disease experiences bleeding, it can be a common ... but it can affect any part of the gastrointestinal (GI) tract from the mouth to the anus.

Notably, there was a "very low" 0.5% incidence of major gastrointestinal bleeding with both doses ... differences in stroke across assigned treatments, though stroke rates trended numerically ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.